Published in J Biol Chem on January 28, 2000
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A (2001) 7.99
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
To differentiate or not--routes towards metastasis. Nat Rev Cancer (2012) 3.59
Investigating stem cells in human colon by using methylation patterns. Proc Natl Acad Sci U S A (2001) 3.56
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest (2002) 3.23
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res (2010) 3.19
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Methylation matters. J Med Genet (2001) 3.00
The p120 catenin partner Kaiso is a DNA methylation-dependent transcriptional repressor. Genes Dev (2001) 2.91
Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol (2009) 2.89
E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer (2006) 2.74
Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res (2009) 2.68
Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol (2003) 2.36
Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer (2010) 2.31
E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis (2008) 2.21
The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res (2001) 2.14
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci U S A (2000) 1.83
GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem (2010) 1.73
Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell (2011) 1.66
Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. Am J Pathol (2015) 1.44
CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer (2006) 1.41
Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer (2004) 1.41
Friend or foe: role of E-cadherin in prostate cancer metastasis. Transl Androl Urol (2016) 1.39
Stable CpG hypomethylation of adipogenic promoters in freshly isolated, cultured, and differentiated mesenchymal stem cells from adipose tissue. Mol Biol Cell (2006) 1.36
Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer (2009) 1.29
Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing and promotes tumour cell motility and invasion. EMBO J (2010) 1.27
Dynamics of adipogenic promoter DNA methylation during clonal culture of human adipose stem cells to senescence. BMC Cell Biol (2007) 1.20
Nuclear speckle-associated protein Pnn/DRS binds to the transcriptional corepressor CtBP and relieves CtBP-mediated repression of the E-cadherin gene. Mol Cell Biol (2004) 1.15
Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet (2009) 1.13
Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Sci Rep (2013) 1.13
Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis. Front Biosci (Landmark Ed) (2011) 1.12
Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis (2006) 1.11
Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci (2013) 1.10
DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat (2008) 1.10
Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol (2013) 1.09
Metastasis suppressors and the tumor microenvironment. Cancer Microenviron (2008) 1.07
Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol (2001) 1.07
Signaling crossroads: the function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal (2007) 1.04
Local regulation of human breast xenograft models. J Cell Physiol (2010) 1.04
Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol (2011) 1.04
The role and function of cadherins in the mammary gland. Breast Cancer Res (2012) 1.03
Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am J Pathol (2002) 0.99
Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb Perspect Biol (2010) 0.98
c-Jun N-Terminal Kinases Mediate a Wide Range of Targets in the Metastatic Cascade. Genes Cancer (2013) 0.98
E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features. Am J Pathol (2001) 0.94
Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer (2011) 0.93
Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn (2005) 0.92
Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet (2003) 0.92
Silencing of mouse Aprt is a gradual process in differentiated cells. Mol Cell Biol (2003) 0.91
Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules. J Korean Med Sci (2005) 0.91
Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. World J Gastroenterol (2003) 0.90
Intratumoral Heterogeneity of the Epigenome. Cancer Cell (2016) 0.90
Epigenetic inactivation of E-cadherin by promoter hypermethylation in oral carcinoma cells. Odontology (2007) 0.89
DNA methylation of E-cadherin is a priming mechanism for prostate development. Dev Biol (2014) 0.89
Gene methylation in non-neoplastic mucosa of gastric cancer: age or Helicobacter pylori related? Am J Pathol (2003) 0.89
Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res (2002) 0.89
Field cancerization in the colon: a role for aberrant DNA methylation? Gastroenterol Rep (Oxf) (2014) 0.88
Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol (2006) 0.88
The 3D tissue microenvironment modulates DNA methylation and E-cadherin expression in squamous cell carcinoma. Epigenetics (2012) 0.86
Seed in soil, with an epigenetic view. Biochim Biophys Acta (2008) 0.86
Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors. Prostate (2009) 0.85
RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients. Transl Oncol (2013) 0.85
Programming the genome in embryonic and somatic stem cells. J Cell Mol Med (2007) 0.85
Emerging role of brain metastases in the prognosis of breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.84
Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer. Exp Ther Med (2010) 0.83
Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. Cancer Lett (2013) 0.83
Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med (2016) 0.82
Differential expression of CD44(S) and variant isoforms v3, v10 in three-dimensional cultures of mouse melanoma cell lines. Clin Exp Metastasis (2002) 0.82
Reduced ING1 levels in breast cancer promotes metastasis. Oncotarget (2014) 0.82
TIMP-1 via TWIST1 induces EMT phenotypes in human breast epithelial cells. Mol Cancer Res (2014) 0.81
DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res (2013) 0.81
Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News Perspect (2009) 0.80
Promoter hypermethylation profiling of distant breast cancer metastases. Breast Cancer Res Treat (2015) 0.79
Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy. Br J Cancer (2005) 0.79
Epigenetic regulation of epithelial-mesenchymal transition. Cell Mol Life Sci (2016) 0.79
The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells. Sci Rep (2015) 0.78
DNMT3B7 expression promotes tumor progression to a more aggressive phenotype in breast cancer cells. PLoS One (2015) 0.78
Analysis of DNA methylation in single circulating tumor cells. Oncogene (2017) 0.76
Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review. Drug Des Devel Ther (2015) 0.76
A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression. Oncotarget (2016) 0.76
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies. Nucleic Acids Res (2015) 0.76
Implications of Hypoxia in Breast Cancer Metastasis to Bone. Int J Mol Sci (2016) 0.75
An Atypical System for Studying Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Sci Rep (2016) 0.75
The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition. Oncotarget (2017) 0.75
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res (1999) 6.10
DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet (2000) 5.72
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 4.99
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res (1998) 4.39
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet (2001) 3.96
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos. Nature (1996) 3.79
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
Cloning and structure of a yeast gene encoding a general transcription initiation factor TFIID that binds to the TATA box. Nature (1989) 3.74
Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res (2000) 3.65
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res (1999) 3.48
Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem (2001) 3.23
Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res (1994) 3.18
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res (1997) 3.09
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
CpG methylation is maintained in human cancer cells lacking DNMT1. Nature (2000) 2.94
Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res (2001) 2.79
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science (1994) 2.65
Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res (1999) 2.62
Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood (1999) 2.57
Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A (1991) 2.55
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res (2001) 2.50
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol (2001) 2.48
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med (1995) 2.47
A novel B cell-derived coactivator potentiates the activation of immunoglobulin promoters by octamer-binding transcription factors. Cell (1992) 2.43
cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol Cell Biol (1996) 2.42
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res (2001) 2.41
Tumor necrosis factor-alpha (TNF-alpha) plays a protective role in acute viralmyocarditis in mice: A study using mice lacking TNF-alpha. Circulation (2001) 2.36
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Methylation-specific PCR simplifies imprinting analysis. Nat Genet (1997) 2.33
High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol (2002) 2.33
An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature (1997) 2.29
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem (1997) 2.27
De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol (1996) 2.26
DNA methylation, chromatin inheritance, and cancer. Oncogene (2001) 2.26
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res (2000) 2.18
Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation (1986) 2.17
Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res (1999) 2.17
Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 2.16
The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci U S A (1988) 2.14
Acute Wernicke's encephalopathy: comparison of magnetic resonance images and autopsy findings. Intern Med (1996) 2.14
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer (2008) 2.13
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res (1997) 2.12
The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. Genes Dev (1995) 2.11
Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res (1992) 2.10
Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res (1980) 2.10
Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res (1999) 2.09
High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci U S A (1991) 2.07
The retinoic acid-inactivating enzyme CYP26 is essential for establishing an uneven distribution of retinoic acid along the anterio-posterior axis within the mouse embryo. Genes Dev (2001) 2.04
Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc Natl Acad Sci U S A (1997) 2.00
MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene (1998) 1.99
Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci U S A (1996) 1.99